Welcome to the spring edition of Oncology & Hematology Review. This issue includes a broad range of topics across key areas including precision medicine, gastrointestinal oncology, breast cancer, prostate cancer, supportive care, and geriatric oncology. Leena Gandhi et al discuss the emerging role of PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancer and María-Victoria Mateos explores treatment options for elderly newly diagnosed multiple myeloma patients. We hope you enjoy this collection of topical articles, and that they provide useful information relevant to your practice and interests.
Foreword – Oncology & Hematology Review, 2015;11(1):13
Welcome to the spring edition of Oncology and Haematology Review (US), which features articles on major aspects of oncology. In the era of targeted therapy, oncologists are faced with an ever-increasing number of therapeutic options, and there is a need for biomarker assays to inform treatment decisions. Our first article, by Conley et al., reviews […]
Translating Promising Biomarkers into Oncology Clinical Practice
Although the literature is replete with biomarker studies that show promise for predicting risk for cancer, response to treatment, or prognosis after diagnosis, the number of biomarker-based tests or assays that are useful in the practice of oncology remains distressingly small.1–3 A biomarker can be used to predict a patient’s prognosis, which is their expected […]
A Systematic Review of Factors Influencing Older Adults’ Hypothetical Treatment Decisions
Cancer is a significant health problem in older persons.1 It is estimated that 42 % of all incident cases and over 60 % of mortality due to cancer occur in persons aged 70 and over.1,2 With the aging of the population there will be a considerable increase in the number of older adults diagnosed with […]
Breast Cancer Screening in Older Women— Current Evidence and Future Perspectives
Breast cancer remains one of the largest contributors to cancer mortality in women in developed countries.1,2 As populations of developed countries are aging, the number of older women who have breast cancer will markedly increase in the upcoming decades. It has been shown that breast cancer prognosis deteriorates with age, even though mortality for other […]
PD-1 and PD-L1 Inhibitors in Advanced Non-small Cell Lung Cancer— Promising Agents and Evolving Questions
The use of immunotherapy in advanced non-small cell lung cancer (NSCLC) has long been investigated in advanced NSCLC. The frequent presence of tumor infiltrating lymphocytes (TILs) noted in numerous tumor types provided early evidence of the potential immunogenicity of several cancers including NSCLC.1,2 However, initial attempts to exploit this therapeutically through tumor vaccines, interleukin (IL)-2, […]
How Should We Treat Elderly Newly Diagnosed Multiple Myeloma Patients?
Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1 % of all cancers and 10 % of hematologic malignancies. It primarily affects older individuals—the median age at the moment of diagnosis is 70 years—and two-thirds of multiple myeloma patients are over 65 years of age when they are first diagnosed. The outcome […]
Mucositis—Supportive Care During Radiotherapy or Chemoradiotherapy of Head and Neck Cancer
The majority of patients undergoing radiation therapy for head and neck (HN) cancer will develop oral mucositis, which is a clinical syndrome characterized by erythema, ulcerations, and odynophagia (see Table 1). It is almost universal and more severe among patients with oral cavity, oropharynx, and nasopharynx primaries.1–3 Although therapeutic ratio and outcomes are improved by […]
Chemotherapy-induced Neuropathy—Where Are We Now?
Chemotherapy-induced neuropathy (CIN), which often results from a number of commonly used oncologic drugs, including taxanes, platinum agents, bortezomib, vinca alkaloids, ixabepilone, and eribulin, is one of the most debilitating symptoms caused by chemotherapy. Most research on this toxicity has focused on paclitaxel and oxaliplatin, both of which are used frequently and can cause severe […]
Cancer Pain and Opioids—Past, Present, and Future
Recent Australian initiatives have improved the use and safety of opioid prescribing. The Cancer Council Australia has recently produced evidence-based clinical practice guidelines for the management of cancer pain in adults. They are intended to guide community prescribers in the rational management of pain with advice on the assessment and nonpharmacologic management of pain as […]
Current and Emerging Therapies in Metastatic Prostate Cancer
Knowledge regarding the mechanisms driving progression of prostate cancer (PC) has improved dramatically in the past few years. This has allowed the accelerated development and approval of multiple drugs with different targets. The wide spectrum of rapid developments in this field warrants a comprehensive review. In this paper we aim to summarize the current standard […]
Two Decades of Progress in the Management of a Rare Disease— Peritoneal Mesothelioma
Progress in Diagnosis The two major symptoms in patients with peritoneal mesothelioma are abdominal pain and abdominal distention. The patient may also show constitutional symptoms, such as weight loss and fever. In women, diffuse malignant peritoneal mesothelioma (DMPM) is frequently diagnosed as an incidental finding. This fact may be responsible for the improved survival as […]
Gastrointestinal Stromal Tumors (GIST)—Paving the Way for Modern Oncology—Epidemiology, Diagnosis, Treatment
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Although they have been recognized as a distinct entity for several decades, it has only been over the past 10–15 years that these tumors have been truly studied and further defined by rigorous diagnostic and molecular criteria. Indeed, one might […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!